World-leading Bio-pharmaceutical company Sanofi is amid various crucial announcements, agreements, cost adjustments, and setbacks in recent activities. The company agreed to lower medicine costs in the US, which led the Trump government to strike deals with several major drugmakers. Sanofi is currently under scrutiny facing a tax fraud probe by French authorities. A second delayed FDA decision on its multiple sclerosis (MS) drug, tolebrutinib, has notably impacted the company's shares, falling 6%.
Amid these challenges, Sanofi has been actively participating in partnerships and development deals. These include a collaboration with South Korea's ADEL to develop an Alzheimer's drug worth up to $1.04 billion, and a strategic collaboration with Dren Bio for developing autoimmune disease therapies with a deal value of up to $1.7 billion. While setbacks in tolebrutinib are disappointing, there are eagerly anticipated opportunities such as Sanofi's acquisition of an Alzheimer's candidate for over USD 1 billion.
Sanofi News Analytics from Tue, 10 Jun 2025 07:00:00 GMT to Sat, 20 Dec 2025 15:06:41 GMT - Rating -4 - Innovation 6 - Information 7 - Rumor -4
